Literature DB >> 19505402

Apicidin, the histone deacetylase inhibitor, suppresses Th1 polarization of murine bone marrow-derived dendritic cells.

I D Jung1, J S Lee, Y I Jeong, C M Lee, J H Chang, S K Jeong, S H Chun, W S Park, J Han, Y K Shin, Y-M Park.   

Abstract

Apicidin is a fungal metabolite shown to exhibit anti-proliferative, anti-invasive, and anti-inflammatory properties by the inhibition of histone deacetylase (HDAC). However, the effects of apicidin on the maturation and immunostimulatory function of dendritic cells (DCs) remain unknown. In this study, we investigated whether apicidin modulates surface molecule expression, cytokine production, endocytosis capacity, and underlying signaling pathways in murine bone marrow-derived DCs. We observed that apicidin significantly attenuated surface molecule expression in LPS-stimulated DCs, suppressed production of interleukin (IL)-12 and proinflammatory cytokines (IL-6 and TNF-alpha) by DCs, and reduced IFN-gama production by T cells. The apicidin-treated DCs were found to be highly efficient in antigen capture via mannose receptor-mediated endocytosis. Apicidin also inhibited LPS-induced MAPK activation and NF-kB nuclear translocation in DCs. Moreover, the apicidin-treated DCs were incapable of inducing Th1 responses and normal cell-mediated immune responses. These novel findings not only provide new insights into the immunopharmacological role of apicidin in terms of its effects on DCs, but also broaden current perspectives of the immunopharmacological functions of apicidin, and have implications for the development of therapeutic adjuvants for the treatment of DC-related acute and chronic diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19505402     DOI: 10.1177/039463200902200227

Source DB:  PubMed          Journal:  Int J Immunopathol Pharmacol        ISSN: 0394-6320            Impact factor:   3.219


  12 in total

1.  Effect of the histone deacetylase inhibitor SNDX-275 on Fas signaling in osteosarcoma cells and the feasibility of its topical application for the treatment of osteosarcoma lung metastases.

Authors:  Nadezhda V Koshkina; Krithi Rao-Bindal; Eugenie S Kleinerman
Journal:  Cancer       Date:  2011-02-01       Impact factor: 6.860

Review 2.  Inhibition of histone deacetylases in inflammatory bowel diseases.

Authors:  Rainer Glauben; Britta Siegmund
Journal:  Mol Med       Date:  2011-02-22       Impact factor: 6.354

Review 3.  The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis.

Authors:  Giuseppe Faraco; Leonardo Cavone; Alberto Chiarugi
Journal:  Mol Med       Date:  2011-02-25       Impact factor: 6.354

4.  Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Authors:  Charles A Dinarello; Gianluca Fossati; Paolo Mascagni
Journal:  Mol Med       Date:  2011-05-05       Impact factor: 6.354

5.  An Activity-Guided Map of Electrophile-Cysteine Interactions in Primary Human T Cells.

Authors:  Ekaterina V Vinogradova; Xiaoyu Zhang; David Remillard; Daniel C Lazar; Radu M Suciu; Yujia Wang; Giulia Bianco; Yu Yamashita; Vincent M Crowley; Michael A Schafroth; Minoru Yokoyama; David B Konrad; Kenneth M Lum; Gabriel M Simon; Esther K Kemper; Michael R Lazear; Sifei Yin; Megan M Blewett; Melissa M Dix; Nhan Nguyen; Maxim N Shokhirev; Emily N Chin; Luke L Lairson; Bruno Melillo; Stuart L Schreiber; Stefano Forli; John R Teijaro; Benjamin F Cravatt
Journal:  Cell       Date:  2020-07-29       Impact factor: 41.582

6.  Natural chalcones as dual inhibitors of HDACs and NF-κB.

Authors:  B Orlikova; M Schnekenburger; M Zloh; F Golais; M Diederich; D Tasdemir
Journal:  Oncol Rep       Date:  2012-06-15       Impact factor: 3.906

7.  Histone deacetylase inhibition alters dendritic cells to assume a tolerogenic phenotype and ameliorates arthritis in SKG mice.

Authors:  Kenta Misaki; Akio Morinobu; Jun Saegusa; Shimpei Kasagi; Masaaki Fujita; Yoshiaki Miyamoto; Fumichika Matsuki; Shunichi Kumagai
Journal:  Arthritis Res Ther       Date:  2011-05-18       Impact factor: 5.156

8.  Regulation of immune responses by histone deacetylase inhibitors.

Authors:  Paul V Licciardi; Tom C Karagiannis
Journal:  ISRN Hematol       Date:  2012-03-18

Review 9.  Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.

Authors:  Sena Kim; Srikanth Santhanam; Sora Lim; Jaebok Choi
Journal:  Int J Mol Sci       Date:  2020-06-16       Impact factor: 5.923

Review 10.  Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy.

Authors:  Debarati Banik; Sara Moufarrij; Alejandro Villagra
Journal:  Int J Mol Sci       Date:  2019-05-07       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.